Eli Lilly’s $5.3B Boost for Mounjaro, Zepbound Supply
Eli Lilly has announced a monumental investment of $5.3 billion to expand manufacturing capabilities at its Lebanon, Indiana, site. This substantial investment, which more than doubles their prior commitment of $3.7 billion, brings the total investment to an impressive $9 billion. The expansion aims to address the overwhelming demand and current supply shortage of Mounjaro and Zepbound, as documented in the FDA’s drug shortage database. According to CEO David Ricks, this move signifies the largest manufacturing investment in synthetic medicine API in U.S. history, geared to significantly increase the supply of these vital, tirzepatide-based drugs. Furthermore, the project promises job creation, adding around 200 new positions and generating over 5,000 construction jobs, fortifying the regional economy.
Key Takeaways
- Eli Lilly’s enlargement of the Indiana manufacturing site involves a $5.3 billion investment.
- The overall investment in the site now totals $9 billion.
- This expansion addresses the high demand and present shortage of Mounjaro and Zepbound.
- Enhanced efficiency, safety, and quality control through advanced technologies and automation.
- Creation of around 200 new jobs and more than 5,000 construction jobs expected.
Tell us what YOU think!
For More Info → → Click Here ← ←
Reference Links:
The Silver Academy — The WikiLeaks of Silver
Kuya Silver Corp — High-Grade Silver
Outcrop Silver — World Class High Grade Silver
Silver Means War!!!
Dolly Varden Silver Corp. — Advancing one of the largest high-grade undeveloped precious metals assets in BC’s Golden Triangle
